Semit Pharmaceuticals And Chemicals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 05-07-2024
- Paid Up Capital ₹ 4.50 M
as on 05-07-2024
- Company Age 43 Year, 2 Months
- Last Filing with ROC 31 Mar 2018
- Open Charges ₹ 12.80 Cr
as on 05-07-2024
- Revenue %
(FY 2018)
- Profit 84.42%
(FY 2018)
- Ebitda 99.06%
(FY 2018)
- Net Worth -0.09%
(FY 2018)
- Total Assets -0.03%
(FY 2018)
About Semit Pharmaceuticals And Chemicals
The Corporate was formerly known as Semit Pharmaceuticals And Chemicals Pvt. Ltd.. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.50 M.
The company currently has active open charges totaling ₹12.80 Cr.
Vivek Naik, Arun Pathak, and Varun Bichu serve as directors at the Company.
- CIN/LLPIN
U24239MH1981PLC025454
- Company No.
025454
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
17 Oct 1981
- Date of AGM
29 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Semit Pharmaceuticals And Chemicals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Varun Bichu  | Additional Director | 28-May-2015 | Current |
| Arun Pathak | Additional Director | 28-May-2015 | Current |
| Vivek Naik | Additional Director | 04-May-2015 | Current |
Financial Performance of Semit Pharmaceuticals And Chemicals.
Semit Pharmaceuticals And Chemicals Ltd., for the financial year ended 2018, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 84.42% increase in profit. The company's net worth dipped by a decrease of 0.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Semit Pharmaceuticals And Chemicals?
In 2018, Semit Pharmaceuticals And Chemicals had a promoter holding of 44.44% and a public holding of 55.56%. The company had 2 Associate Companies. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Trustee Services Limited Creation Date: 27 May 2015 | ₹12.00 Cr | Open |
Indian Bank Creation Date: 11 May 1992 | ₹0.46 M | Open |
Indian Bank Creation Date: 10 Jan 1992 | ₹3.40 M | Open |
How Many Employees Work at Semit Pharmaceuticals And Chemicals?
Unlock and access historical data on people associated with Semit Pharmaceuticals And Chemicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Semit Pharmaceuticals And Chemicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Semit Pharmaceuticals And Chemicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
